Cargando…

A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis

BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jian-Zhong, Xiang, Jing-Jun, Wu, Li-Ge, Bai, Yan-Sen, Chen, Zhuo-Wang, Yin, Xiang-Qian, Wang, Qing, Guo, Wen-Hao, Peng, Ying, Guo, Huan, Xu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335789/
https://www.ncbi.nlm.nih.gov/pubmed/28253859
http://dx.doi.org/10.1186/s12885-017-3151-6
_version_ 1782512106189357056
author Wang, Jian-Zhong
Xiang, Jing-Jun
Wu, Li-Ge
Bai, Yan-Sen
Chen, Zhuo-Wang
Yin, Xiang-Qian
Wang, Qing
Guo, Wen-Hao
Peng, Ying
Guo, Huan
Xu, Ping
author_facet Wang, Jian-Zhong
Xiang, Jing-Jun
Wu, Li-Ge
Bai, Yan-Sen
Chen, Zhuo-Wang
Yin, Xiang-Qian
Wang, Qing
Guo, Wen-Hao
Peng, Ying
Guo, Huan
Xu, Ping
author_sort Wang, Jian-Zhong
collection PubMed
description BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. METHODS: We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. RESULTS: It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. CONCLUSIONS: The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3151-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5335789
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53357892017-03-07 A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis Wang, Jian-Zhong Xiang, Jing-Jun Wu, Li-Ge Bai, Yan-Sen Chen, Zhuo-Wang Yin, Xiang-Qian Wang, Qing Guo, Wen-Hao Peng, Ying Guo, Huan Xu, Ping BMC Cancer Research Article BACKGROUND: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. METHODS: We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. RESULTS: It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. CONCLUSIONS: The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3151-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-03 /pmc/articles/PMC5335789/ /pubmed/28253859 http://dx.doi.org/10.1186/s12885-017-3151-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Jian-Zhong
Xiang, Jing-Jun
Wu, Li-Ge
Bai, Yan-Sen
Chen, Zhuo-Wang
Yin, Xiang-Qian
Wang, Qing
Guo, Wen-Hao
Peng, Ying
Guo, Huan
Xu, Ping
A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title_full A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title_fullStr A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title_full_unstemmed A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title_short A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
title_sort genetic variant in long non-coding rna malat1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335789/
https://www.ncbi.nlm.nih.gov/pubmed/28253859
http://dx.doi.org/10.1186/s12885-017-3151-6
work_keys_str_mv AT wangjianzhong ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT xiangjingjun ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT wulige ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT baiyansen ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT chenzhuowang ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT yinxiangqian ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT wangqing ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT guowenhao ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT pengying ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT guohuan ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT xuping ageneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT wangjianzhong geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT xiangjingjun geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT wulige geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT baiyansen geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT chenzhuowang geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT yinxiangqian geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT wangqing geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT guowenhao geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT pengying geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT guohuan geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis
AT xuping geneticvariantinlongnoncodingrnamalat1associatedwithsurvivaloutcomeamongpatientswithadvancedlungadenocarcinomaasurvivalcohortanalysis